Skip to main content
NCBI home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2024 Aug;28(43):1–210. doi: 10.3310/JRYT3981

The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation.

Moira Cruickshank, Jemma Hudson, Rodolfo Hernández, Magaly Aceves-Martins, Richard Quinton, Katie Gillies, Lorna S Aucott, Charlotte Kennedy, Paul Manson, Nicholas Oliver, Frederick Wu, Siladitya Bhattacharya, Waljit S Dhillo, Channa N Jayasena, Miriam Brazzelli
PMCID: PMC11404359  PMID: 39248210

Abstract

BACKGROUND

Low levels of testosterone cause male hypogonadism, which is associated with sexual dysfunction, tiredness and reduced muscle strength and quality of life. Testosterone replacement therapy is commonly used for ameliorating symptoms of male hypogonadism, but there is uncertainty about the magnitude of its effects and its cardiovascular and cerebrovascular safety.

AIMS OF THE RESEARCH

The primary aim was to evaluate the safety of testosterone replacement therapy. We also assessed the clinical and cost-effectiveness of testosterone replacement therapy for men with male hypogonadism, and the existing qualitative evidence on men's experience and acceptability of testosterone replacement therapy.

DESIGN

Evidence synthesis and individual participant data meta-analysis of effectiveness and safety, qualitative evidence synthesis and model-based cost-utility analysis.

DATA SOURCES

Major electronic databases were searched from 1992 to February 2021 and were restricted to English-language publications.

METHODS

We conducted a systematic review with meta-analysis of individual participant data according to current methodological standards. Evidence was considered from placebo-controlled randomised controlled trials assessing the effects of any formulation of testosterone replacement therapy in men with male hypogonadism. Primary outcomes were mortality and cardiovascular and cerebrovascular events. Data were extracted by one reviewer and cross-checked by a second reviewer. The risk of bias was assessed using the Cochrane Risk of Bias tool. We performed one-stage meta-analyses using the acquired individual participant data and two-stage meta-analyses to integrate the individual participant data with data extracted from eligible studies that did not provide individual participant data. A decision-analytic Markov model was developed to evaluate the cost per quality-adjusted life-years of the use of testosterone replacement therapy in cohorts of patients of different starting ages.

RESULTS

We identified 35 trials (5601 randomised participants). Of these, 17 trials (3431 participants) provided individual participant data. There were too few deaths to assess mortality. There was no difference between the testosterone replacement therapy group (120/1601, 7.5%) and placebo group (110/1519, 7.2%) in the incidence of cardiovascular and/or cerebrovascular events (13 studies, odds ratio 1.07, 95% confidence interval 0.81 to 1.42; p = 0.62). Testosterone replacement therapy improved quality of life and sexual function in almost all patient subgroups. In the testosterone replacement therapy group, serum testosterone was higher while serum cholesterol, triglycerides, haemoglobin and haematocrit were all lower. We identified several themes from five qualitative studies showing how symptoms of low testosterone affect men's lives and their experience of treatment. The cost-effectiveness of testosterone replacement therapy was dependent on whether uncertain effects on all-cause mortality were included in the model, and on the approach used to estimate the health state utility increment associated with testosterone replacement therapy, which might have been driven by improvements in symptoms such as sexual dysfunction and low mood.

LIMITATIONS

A meaningful evaluation of mortality was hampered by the limited number of defined events. Definition and reporting of cardiovascular and cerebrovascular events and methods for testosterone measurement varied across trials.

CONCLUSIONS

Our findings do not support a relationship between testosterone replacement therapy and cardiovascular/cerebrovascular events in the short-to-medium term. Testosterone replacement therapy improves sexual function and quality of life without adverse effects on blood pressure, serum lipids or glycaemic markers.

FUTURE WORK

Rigorous long-term evidence assessing the safety of testosterone replacement therapy and subgroups most benefiting from treatment is needed.

STUDY REGISTRATION

The study is registered as PROSPERO CRD42018111005.

FUNDING

This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 17/68/01) and is published in full in Health Technology Assessment; Vol. 28, No. 43. See the NIHR Funding and Awards website for further award information.

Plain language summary

Testosterone is a hormone which is vital for sexual activity, bone growth and muscle development in men. Men with low testosterone levels may experience problems with erections and may suffer from brittle bones (osteoporosis), weakness, feeling down (low mood) and tiredness. The manifestations of low testosterone can be treated with testosterone replacement therapy. However, there is current uncertainty about the positive effects of testosterone replacement therapy and its safety. We brought together results from all available medical studies that looked at the use of testosterone replacement therapy in men with low testosterone and contacted the doctors who led these studies to gather further information on their participants. We found 35 studies (5601 participants) conducted in different countries, 17 of which provided additional information on their participants. We did not find any evidence to show that testosterone replacement therapy increases the risk of heart problems, or any evidence to show that some men who take testosterone replacement therapy benefit more than others. Men with low testosterone reported having low mood, poor concentration and lack of energy; however, medical studies often failed to prove that these manifestations improved with testosterone replacement therapy. Most medical studies were conducted among white men in North America using questionnaires designed specifically for them; therefore, the results may not reflect the experiences of men in other countries and from more diverse ethnic backgrounds. There is too much uncertainty about the benefits of testosterone replacement therapy to accurately estimate its value for money for the NHS. We think our findings offer some reassurance to doctors and patients that testosterone replacement therapy does not increase the risk of heart problems. New studies are needed to find out whether some groups of men (such as older or younger men) are more likely to benefit from testosterone replacement therapy more than others. It is also important to develop tools which better reflect the experience of men from a diverse range of social and ethnic backgrounds. To inform men with low testosterone about our findings, we are creating a website with dedicated YouTube video clips.

Full text of this article can be found in Bookshelf.

References

  1. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2018;103(5):1715–44. doi: 10.1210/jc.2018-00229. [DOI] [PubMed]
  2. Handelsman DJ. Androgen physiology, pharmacology, use and misuse. In Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al., editors. Endotext. South Dartmouth, MA: MDText.com, Inc.; 2000. [PubMed]
  3. Corona G, Goulis DG, Huhtaniemi I, Zitzmann M, Toppari J, Forti G, et al. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: endorsing organization: European Society of Endocrinology. Andrology 2020;8(5):970–87. doi: 10.1111/andr.12770. [DOI] [PubMed]
  4. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al.; EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363(2):123–35. doi: 10.1056/NEJMoa0911101. [DOI] [PubMed]
  5. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151(1):54–61. doi: 10.1016/s0022-5347(17)34871-1. [DOI] [PubMed]
  6. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med 2003;139(3):161–8. doi: 10.7326/0003-4819-139-3-200308050-00005. [DOI] [PubMed]
  7. Al-Sharefi A, Quinton R. Current national and international guidelines for the management of male hypogonadism: helping clinicians to navigate variation in diagnostic criteria and treatment recommendations. Endocrinol Metab (Seoul) 2020;35(3):526–40. doi: 10.3803/EnM.2020.760. [DOI] [PMC free article] [PubMed]
  8. Kwong JCC, Krakowsky Y, Grober E. Testosterone deficiency: a review and comparison of current guidelines. J Sex Med 2019;16(6):812–20. doi: 10.1016/j.jsxm.2019.03.262. [DOI] [PubMed]
  9. Rosen RC, Wu F, Behre HM, Porst H, Meuleman EJH, Maggi M, et al.; RHYME Investigators. Quality of life and sexual function benefits of long-term testosterone treatment: longitudinal results from the Registry of Hypogonadism in Men (RHYME). J Sex Med 2017;14(9):1104–15. doi: 10.1016/j.jsxm.2017.07.004. [DOI] [PubMed]
  10. Travison TG, Vesper HW, Orwoll E, Wu F, Kaufman JM, Wang Y, et al. Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe. J Clin Endocrinol Metab 2017;102(4):1161–73. doi: 10.1210/jc.2016-2935. [DOI] [PMC free article] [PubMed]
  11. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al.; Testosterone Trials Investigators. Effects of testosterone treatment in older men. N Engl J Med 2016;374(7):611–24. doi: 10.1056/NEJMoa1506119. [DOI] [PMC free article] [PubMed]
  12. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363(2):109–22. doi: 10.1056/NEJMoa1000485. [DOI] [PMC free article] [PubMed]
  13. Gan EH, Pattman S, S HSP, Quinton R. A UK epidemic of testosterone prescribing, 2001-2010. Clin Endocrinol (Oxf) 2013;79(4):564–70. doi: 10.1111/cen.12178. [DOI] [PubMed]
  14. Sansone A, Sansone M, Lenzi A, Romanelli F. Testosterone replacement therapy: the Emperor’s new clothes. Rejuvenation Res 2017;20(1):9–14. doi: 10.1089/rej.2016.1818. [DOI] [PubMed]
  15. NHS England. The ‘Male Menopause’ 2019. URL: www.nhs.uk/conditions/male-menopause/ (accessed 7 May 2021).
  16. Food and Drug Administration. FDA Drug Safety Communication: FDA Cautions About Using Testosterone Products for Low Testosterone Due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of Heart Attack and Stroke With Use; 2015. URL: www.fda.gov/media/91048/download (accessed 7 May 2021). doi: 10.1016/j.juro.2015.06.058. [DOI] [PubMed]
  17. Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95(6):2560–75. doi: 10.1210/jc.2009-2575. [DOI] [PubMed]
  18. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013;11:108. doi: 10.1186/1741-7015-11-108. [DOI] [PMC free article] [PubMed]
  19. Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, Maggi M. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf 2014;13(10):1327–51. doi: 10.1517/14740338.2014.950653. [DOI] [PubMed]
  20. Borst SE, Shuster JJ, Zou B, Ye F, Jia H, Wokhlu A, Yarrow JF. Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. BMC Med 2014;12:211. doi: 10.1186/s12916-014-0211-5. [DOI] [PMC free article] [PubMed]
  21. Seftel AD, Kathrins M, Niederberger C. Critical update of the 2010 Endocrine Society clinical practice guidelines for male hypogonadism: a systematic analysis. Mayo Clin Proc 2015;90(8):1104–15. doi: 10.1016/j.mayocp.2015.06.002. [DOI] [PubMed]
  22. Albert SG, Morley JE. Testosterone therapy, association with age, initiation and mode of therapy with cardiovascular events: a systematic review. Clin Endocrinol (Oxf) 2016;85(3):436–43. doi: 10.1111/cen.13084. [DOI] [PubMed]
  23. Guo C, Gu W, Liu M, Peng BO, Yao X, Yang B, Zheng J. Efficacy and safety of testosterone replacement therapy in men with hypogonadism: a meta-analysis study of placebo-controlled trials. Exp Ther Med 2016;11(3):853–63. doi: 10.3892/etm.2015.2957. [DOI] [PMC free article] [PubMed]
  24. Huo S, Scialli AR, McGarvey S, Hill E, Tügertimur B, Hogenmiller A, et al. Treatment of men for ‘low testosterone’: a systematic review. PLOS ONE 2016;11(9):e0162480. doi: 10.1371/journal.pone.0162480. [DOI] [PMC free article] [PubMed]
  25. Corona G, Rastrelli G, Morgentaler A, Sforza A, Mannucci E, Maggi M. Meta-analysis of results of testosterone therapy on sexual function based on international index of erectile function scores. Eur Urol 2017;72(6):1000–11. doi: 10.1016/j.eururo.2017.03.032. [DOI] [PubMed]
  26. Alexander GC, Iyer G, Lucas E, Lin D, Singh S. Cardiovascular risks of exogenous testosterone use among men: a systematic review and meta-analysis. Am J Med 2017;130(3):293–305. doi: 10.1016/j.amjmed.2016.09.017. [DOI] [PubMed]
  27. Szeinbach SL, Seoane-Vazquez E, Summers KH. Development of a men’s Preference for Testosterone Replacement Therapy (P-TRT) instrument. Patient Prefer Adherence 2012;6:631–41. doi: 10.2147/PPA.S35840. [DOI] [PMC free article] [PubMed]
  28. Mascarenhas A, Khan S, Sayal R, Knowles S, Gomes T, Moore JE. Factors that may be influencing the rise in prescription testosterone replacement therapy in adult men: a qualitative study. Aging Male 2016;19(2):90–5. doi: 10.3109/13685538.2016.1150994. [DOI] [PubMed]
  29. Dunning TL, Ward GM. Testosterone replacement therapy – perceptions of recipients and partners. J Adv Nurs 2004;47(5):467–74. doi: 10.1111/j.1365-2648.2004.03124.x. [DOI] [PubMed]
  30. Hackett G, Kirby M, Edwards D, Jones TH, Wylie K, Ossei-Gerning N, et al. British Society for Sexual Medicine guidelines on adult testosterone deficiency, with statements for UK practice. J Sex Med 2017;14(12):1504–23. doi: 10.1016/j.jsxm.2017.10.067. [DOI] [PubMed]
  31. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95(6):2536–59. doi: 10.1210/jc.2009-2354. [DOI] [PubMed]
  32. Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, et al.; Standardized Data Collection for Cardiovascular Trials Initiative (SCTI). 2017 Cardiovascular and stroke endpoint definitions for clinical trials. J Am Coll Cardiol 2018;71(9):1021–34. doi: 10.1016/j.jacc.2017.12.048. [DOI] [PubMed]
  33. StataCorp. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC; 2019.
  34. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0; 2011. URL: http://handbook-5-1.cochrane.org/ (accessed 29 April 2021).
  35. Maruish M. User’s manual for the SF-36v2 Health Survey. 3rd edn. Lincoln, RI: QualityMetric Incorporated; 2011.
  36. Efthimiou O. Practical guide to the meta-analysis of rare events. Evid Based Ment Health 2018;21(2):72–6. doi: 10.1136/eb-2018-102911. [DOI] [PMC free article] [PubMed]
  37. Riley RD, Debray TPA, Fisher D, Hattle M, Marlin N, Hoogland J, et al. Individual participant data meta-analysis to examine interactions between treatment effect and participant-level covariates: statistical recommendations for conduct and planning. Stat Med 2020;39(15):2115–37. doi: 10.1002/sim.8516. [DOI] [PMC free article] [PubMed]
  38. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004;89(2):503–10. doi: 10.1210/jc.2003-031110. [DOI] [PubMed]
  39. Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA 2015;314(6):570–81. doi: 10.1001/jama.2015.8881. [DOI] [PubMed]
  40. Hildreth KL, Barry DW, Moreau KL, Vande Griend J, Meacham RB, Nakamura T, et al. Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab 2013;98(5):1891–900. doi: 10.1210/jc.2012-3695. [DOI] [PMC free article] [PubMed]
  41. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism – a randomized controlled trial. JAMA 2006;296(19):2351–61. doi: 10.1001/jama.296.19.2351. [DOI] [PubMed]
  42. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med 2013;10(6):1612–27. doi: 10.1111/jsm.12146. [DOI] [PubMed]
  43. Merza Z, Blumsohn A, Mah PM, Meads DM, McKenna SP, Wylie K, et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. Int J Androl 2006;29(3):381–91. doi: 10.1111/j.1365-2605.2005.00612.x. [DOI] [PubMed]
  44. Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MD, Adams JE, Oldham JA, Wu FCW. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010;95(2):639–50. doi: 10.1210/jc.2009-1251. [DOI] [PubMed]
  45. Emmelot-Vonk MH, Verhaar HJJ, Pour HRN, Aleman A, Lock T, Bosch J, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men – a randomized controlled trial. JAMA 2008;299(1):39–52. doi: 10.1001/jama.2007.51. [DOI] [PubMed]
  46. Gianatti EJ, Dupuis P, Hoermann R, Zajac JD, Grossmann M. Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab 2014;99(10):3821–8. doi: 10.1210/jc.2014-1872. [DOI] [PubMed]
  47. Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJ, Saad F, Kalinchenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 2010;7(7):2572–82. doi: 10.1111/j.1743-6109.2010.01859.x. [DOI] [PubMed]
  48. Groti K, Žuran I, Antonič B, Foršnarič L, Pfeifer M. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male 2018;21(3):158–69. doi: 10.1080/13685538.2018.1468429. [DOI] [PubMed]
  49. Ho CC, Tong SF, Low WY, Ng CJ, Khoo EM, Lee VK, et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU Int 2012;110(2):260–5. doi: 10.1111/j.1464-410X.2011.10755.x. [DOI] [PubMed]
  50. Magnussen LV, Glintborg D, Hermann P, Hougaard DM, Højlund K, Andersen M. Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy. Diabetes Obes Metab 2016;18(10):980–9. doi: 10.1111/dom.12701. [DOI] [PubMed]
  51. Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 2008;20(4):378–87. doi: 10.1038/ijir.2008.19. [DOI] [PubMed]
  52. Brock G, Heiselman D, Maggi M, Kim SW, Rodríguez Vallejo JM, Behre HM, et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. J Urol 2016;195(3):699–705. doi: 10.1016/j.juro.2015.10.083. [DOI] [PubMed]
  53. Borst SE, Yarrow JF, Conover CF, Nseyo U, Meuleman JR, Lipinska JA, et al. Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial. Am J Physiol Endocrinol Metab 2014;306(4):E433–42. doi: 10.1152/ajpendo.00592.2013. [DOI] [PMC free article] [PubMed]
  54. Cherrier MM, Anderson K, Shofer J, Millard S, Matsumoto AM. Testosterone treatment of men with mild cognitive impairment and low testosterone levels. Am J Alzheimers Dis Other Demen 2015;30(4):421–30. doi: 10.1177/1533317514556874. [DOI] [PMC free article] [PubMed]
  55. Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Sandhu S, et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care 2016;39(1):82–91. doi: 10.2337/dc15-1518. [DOI] [PMC free article] [PubMed]
  56. Dias JP, Melvin D, Simonsick EM, Carlson O, Shardell MD, Ferrucci L, et al. Effects of aromatase inhibition vs. testosterone in older men with low testosterone: randomized-controlled trial. Andrology 2016;4(1):33–40. doi: 10.1111/andr.12126. [DOI] [PMC free article] [PubMed]
  57. Kaufman JM, Miller MG, Garwin JL, Fitzpatrick S, McWhirter C, Brennan JJ. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med 2011;8(7):2079–89. doi: 10.1111/j.1743-6109.2011.02265.x. [DOI] [PubMed]
  58. Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, McGee D. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc 2010;58(6):1134–43. doi: 10.1111/j.1532-5415.2010.02865.x. [DOI] [PMC free article] [PubMed]
  59. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand RAA. 2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003;88(6):2673–81. doi: 10.1210/jc.2002-021058. [DOI] [PubMed]
  60. Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, Spera G. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010a;7(10):3495–503. doi: 10.1111/j.1743-6109.2010.01931.x. [DOI] [PubMed]
  61. Aversa A, Bruzziches R, Francomano D, Spera G, Lenzi A. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. J Endocrinol Invest 2010b;33(11):776–83. doi: 10.1007/BF03350341. [DOI] [PubMed]
  62. Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology 2004;63(4):641–6. doi: 10.1016/j.urology.2003.11.009. [DOI] [PubMed]
  63. Basurto L, Zarate A, Gomez R, Vargas C, Saucedo R, Galvan R. Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men. Aging Male 2008;11(3):140–5. doi: 10.1080/13685530802273715. [DOI] [PubMed]
  64. Chiang HS, Hwang TI, Hsui YS, Lin YC, Chen HE, Chen GC, Liao CH. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. Int J Impot Res 2007;19(4):411–7. doi: 10.1038/sj.ijir.3901562. [DOI] [PubMed]
  65. Clague JE, Wu FC, Horan MA. Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men. Int J Androl 1999;22(4):261–5. doi: 10.1046/j.1365-2605.1999.00177.x. [DOI] [PubMed]
  66. Morales A, Black A, Emerson L, Barkin J, Kuzmarov I, Day A. Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male 2009;12(4):104–12. doi: 10.3109/13685530903294388. [DOI] [PubMed]
  67. Wang YJ, Zhan JK, Huang W, Wang Y, Liu Y, Wang S, et al. Effects of low-dose testosterone undecanoate treatment on bone mineral density and bone turnover markers in elderly male osteoporosis with low serum testosterone. Int J Endocrinol 2013;2013:570413. doi: 10.1155/2013/570413. [DOI] [PMC free article] [PubMed]
  68. Behre HM, Tammela TL, Arver S, Tolrá JR, Bonifacio V, Lamche M, et al.; European Testogel® Study Team. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male 2012;15(4):198–207. doi: 10.3109/13685538.2012.699562. [DOI] [PubMed]
  69. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, et al.; TIMES2 Investigators. Testosterone replacement in hypogonadal men with Type 2 diabetes and/or metabolic syndrome (the TIMES2 Study). Diabetes Care. 2011;34(4):828–37. doi: 10.2337/dc10-1233. [DOI] [PMC free article] [PubMed]
  70. Paduch DA, Polzer PK, Ni X, Basaria S. Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. J Clin Endocrinol Metab 2015;100(8):2956–62. doi: 10.1210/jc.2014-4434. [DOI] [PubMed]
  71. Bayer AG. Testosterone Conversion Tool; 2021. URL: www.nebido.com/hcp/tools/testosterone-unit-conversion (accessed 30 April 2021).
  72. Diem SJ, Greer NL, MacDonald R, McKenzie LG, Dahm P, Ercan-Fang N, et al. Efficacy and safety of testosterone treatment in men: an evidence report for a clinical practice guideline by the American College of Physicians. Ann Intern Med 2020;172(2):105–18. doi: 10.7326/M19-0830. [DOI] [PubMed]
  73. Bachman E, Feng R, Travison T, Li M, Olbina G, Ostland V, et al. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. J Clin Endocrinol Metab 2010;95(10):4743–7. doi: 10.1210/jc.2010-0864. [DOI] [PMC free article] [PubMed]
  74. Hackett G, Cole N, Mulay A, Strange RC, Ramachandran S. Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors. BJU Int 2019;123(3):519–29. doi: 10.1111/bju.14536. [DOI] [PubMed]
  75. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013;169(6):725–33. doi: 10.1530/EJE-13-0321. [DOI] [PubMed]
  76. National Library of Medicine. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE); 2018. URL: www.clinicaltrials.gov/ct2/show/ NCT03518034?term= NCT03518034&draw=2&rank=1 (accessed August 2021).
  77. Miller WR. Qualitative research findings as evidence: utility in nursing practice. Clin Nurse Spec 2010;24(4):191–3. doi: 10.1097/NUR.0b013e3181e36087. [DOI] [PMC free article] [PubMed]
  78. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol 2008;8:45. doi: 10.1186/1471-2288-8-45. [DOI] [PMC free article] [PubMed]
  79. Critical Appraisal Skills Programme. CASP Qualitative Check List. Oxford: Critical Appraisal Skills Programme; 2018. URL: https://casp-uk.b-cdn.net/wp-content/uploads/2018/03/CASP-Qualitative-Checklist-2018_fillable_form.pdf (accessed May 2021).
  80. Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gülmezoglu M, et al. Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from evidence syntheses (GRADE-CERQual). PLOS Med 2015;12(10):e1001895. doi: 10.1371/journal.pmed.1001895. [DOI] [PMC free article] [PubMed]
  81. Hayes RP, Henne J, Kinchen KS. Establishing the content validity of the Sexual Arousal, Interest, and Drive Scale and the hypogonadism energy diary. Int J Clin Pract 2015;69(4):454–65. doi: 10.1111/ijcp.12542. [DOI] [PubMed]
  82. Gelhorn HL, Vernon MK, Stewart KD, Miller MG, Brod M, Althof SE, et al. Content validity of the hypogonadism impact of symptoms questionnaire (HIS-Q): a patient-reported outcome measure to evaluate symptoms of hypogonadism. Patient 2016;9(2):181–90. doi: 10.1007/s40271-015-0138-8. [DOI] [PubMed]
  83. Gelhorn HL, Bodhani AR, Wahala LS, Sexton C, Landrian A, Miller MG, et al. Development of the Hypogonadism Impact of Symptoms Questionnaire Short Form: qualitative research. J Sex Med 2016b;13(11):1729–36. doi: 10.1016/j.jsxm.2016.09.007. [DOI] [PubMed]
  84. Rosen RC, Araujo AB, Connor MK, Elstad EA, McGraw SA, Guay AT, et al. Assessing symptoms of hypogonadism by self-administered questionnaire: qualitative findings in patients and controls. Aging Male 2009;12(2–3):77–85. doi: 10.1080/13685530903184043. [DOI] [PubMed]
  85. Chambers SK, Chung E, Wittert G, Hyde MK. Erectile dysfunction, masculinity, and psychosocial outcomes: a review of the experiences of men after prostate cancer treatment. Transl Androl Urol 2017;6(1):60–8. doi: 10.21037/tau.2016.08.12. [DOI] [PMC free article] [PubMed]
  86. Wentzell E. How did erectile dysfunction become ‘natural?’ A review of the critical social scientific literature on medical treatment for male sexual dysfunction. J Sex Res 2017;54(4–5):486–506. doi: 10.1080/00224499.2016.1259386. [DOI] [PubMed]
  87. King AJ, Evans M, Moore TH, Paterson C, Sharp D, Persad R, Huntley AL. Prostate cancer and supportive care: a systematic review and qualitative synthesis of men’s experiences and unmet needs. Eur J Cancer Care (Engl) 2015;24(5):618–34. doi: 10.1111/ecc.12286. [DOI] [PMC free article] [PubMed]
  88. Zaider T, Manne S, Nelson C, Mulhall J, Kissane D. Loss of masculine identity, marital affection, and sexual bother in men with localized prostate cancer. J Sex Med 2012;9(10):2724–32. doi: 10.1111/j.1743-6109.2012.02897.x. [DOI] [PMC free article] [PubMed]
  89. Seidler ZE, Dawes AJ, Rice SM, Oliffe JL, Dhillon HM. The role of masculinity in men’s help-seeking for depression: a systematic review. Clin Psychol Rev 2016;49:106–18. doi: 10.1016/j.cpr.2016.09.002. [DOI] [PubMed]
  90. Handelsman DJ. Pharmacoepidemiology of testosterone prescribing in Australia, 1992-2010. Med J Aust 2012;196(10):642–5. doi: 10.5694/mja11.11277. [DOI] [PubMed]
  91. Bhugra D, Silva PD. Sexual dysfunction across cultures. Int Rev Psychiatry 1993;5(2–3):243–52.
  92. Black N. Patient reported outcome measures could help transform healthcare. BMJ 2013;346:f167. doi: 10.1136/bmj.f167. [DOI] [PubMed]
  93. Langham S, Maggi M, Schulman C, Quinton R, Uhl-Hochgraeber K. Health-related quality of life instruments in studies of adult men with testosterone deficiency syndrome: a critical assessment. J Sex Med 2008;5(12):2842–52. doi: 10.1111/j.1743-6109.2008.01015.x. [DOI] [PubMed]
  94. Macefield RC, Jacobs M, Korfage IJ, Nicklin J, Whistance RN, Brookes ST, et al. Developing core outcomes sets: methods for identifying and including patient-reported outcomes (PROs). Trials 2014;15:49. doi: 10.1186/1745-6215-15-49. [DOI] [PMC free article] [PubMed]
  95. Gillies K, Duthie A, Cotton S, Campbell MK. Patient reported measures of informed consent for clinical trials: a systematic review. PLOS ONE 2018;13(6):e0199775. doi: 10.1371/journal.pone.0199775. [DOI] [PMC free article] [PubMed]
  96. Cruickshank M, Newlands R, Blazeby J, Ahmed I, Bekheit M, Brazzelli M, et al. Identification and categorisation of relevant outcomes for symptomatic uncomplicated gallstone disease: in-depth analysis to inform the development of a core outcome set. BMJ Open 2021;11(6):e045568. doi: 10.1136/bmjopen-2020-045568. [DOI] [PMC free article] [PubMed]
  97. Potter WJ, Levine‐Donnerstein D. Rethinking validity and reliability in content analysis. J Appl Commun Res 1999;27(3):258–84.
  98. World Health Organization. International Classification of Functioning, Disability and Health (ICF); 2001. URL: www.who.int/standards/classifications/international-classification-of-functioning-disability-and-health (accessed 4 August 2020).
  99. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry HM. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49(9):1239–42. doi: 10.1053/meta.2000.8625. [DOI] [PubMed]
  100. Heinemann L, Saad F, Pöllänen P. Measurement of quality of life specific for aging males. In Schneider HPG, editor. Hormone Replacement Therapy and Quality of Life. London: Parthenon; 2002.
  101. Heinemann LA, Saad F, Zimmermann T, Novak A, Myon E, Badia X, et al. The Aging Males’ Symptoms (AMS) scale: update and compilation of international versions. Health Qual Life Outcomes 2003;1:15. doi: 10.1186/1477-7525-1-15. [DOI] [PMC free article] [PubMed]
  102. Heinemann LAJ, Saad F, Thiele K, Wood-Dauphinee S. The Aging Males’ Symptoms rating scale: cultural and linguistic validation into English. Aging Male 2001;4(1):14–22.
  103. Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel C, Hummel W. A new ‘aging males’ symptoms’ rating scale. Aging Male 1999;2(2):105–14.
  104. Corona G, Mannucci E, Petrone L, Balercia G, Fisher AD, Chiarini V, et al. ANDROTEST: a structured interview for the screening of hypogonadism in patients with sexual dysfunction. J Sex Med 2006;3(4):706–15. doi: 10.1111/j.1743-6109.2006.00262.x. [DOI] [PubMed]
  105. McMillan CV, Bradley C, Giannoulis M, Martin F, Sönksen PH. Preliminary development of a new individualised questionnaire measuring quality of life in older men with age-related hormonal decline: the A-RHDQoL. Health Qual Life Outcomes 2003;1:51. doi: 10.1186/1477-7525-1-51. [DOI] [PMC free article] [PubMed]
  106. Gelhorn HL, Dashiell-Aje E, Miller MG, DeRogatis LR, Dobs A, Seftel AD, et al. Psychometric evaluation of the hypogonadism impact of symptoms questionnaire. J Sex Med 2016c;13(11):1737–49. doi: 10.1016/j.jsxm.2016.09.006. [DOI] [PubMed]
  107. Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf) 2000;53(6):703–11. doi: 10.1046/j.1365-2265.2000.01152.x. [DOI] [PubMed]
  108. Morales A, Lunenfeld B; International Society for the Study of the Aging Male. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International society for the study of the aging male. Aging Male 2002;5(2):74–86. [PubMed]
  109. Bradley C. Age-Related Hormone Deficiency-Dependent Quality of Life (A-RHDQoL). Egham, UK: Health Psychology Research Unit, University of London; 2001. URL: www.healthpsychologyresearch.com/find-a-questionnaire/age-related-hormone-deficiency-dependent-quality-life-rhdqol (accessed 11 August 2020).
  110. Wiltink J, Beutel ME, Brähler E, Weidner W. Hypogonadism-related symptoms: development and evaluation of an empirically derived self-rating instrument (HRS ‘Hypogonadism Related Symptom Scale’). Andrologia 2009;41(5):297–304. doi: 10.1111/j.1439-0272.2009.00930.x. [DOI] [PubMed]
  111. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al.; CHEERS Task Force. Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health 2013;16(2):e1–5. doi: 10.1016/j.jval.2013.02.010. [DOI] [PubMed]
  112. Arver S, Luong B, Fraschke A, Ghatnekar O, Stanisic S, Gultyev D, Müller E. Is testosterone replacement therapy in males with hypogonadism cost-effective? An analysis in Sweden. J Sex Med 2014;11(1):262–72. doi: 10.1111/jsm.12277. [DOI] [PubMed]
  113. TreeAge Software LLC. TreeAge Pro. Williamstown, MA: TreeAge Software LLC; 2020.
  114. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal [PMG9] 2013 updated 4 March 2020. www.nice.org.uk/process/pmg9/chapter/foreword (accessed August 2021). [PubMed]
  115. British Heart Foundation. Heart and Circulatory Disease Statistics 2020; 2020. www.bhf.org.uk/what-we-do/our-research/heart-statistics/heart-statistics-publications/cardiovascular-disease-statistics-2020 (accessed August 2021).
  116. Office for National Statistics. National Life Tables: UK; 2020. www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables (accessed August 2021).
  117. National Institute for Health and Care Excellence. Acute Coronary Syndromes Cost-effectiveness Analysis: Which Dual Antiplatelet Therapy is Most Cost Effective for Managing Unstable Angina or NSTEMI or for Managing STEMI in Adults Undergoing PCI? (NG185). London/Manchester: National Institute for Health and Care Excellence; 2020. www.nice.org.uk/guidance/ng185/evidence/health-economic-analysis-for-dual-antiplatelet-therapy-pdf-8903834893 (accessed 9 September 2020).
  118. Smolina K, Wright FL, Rayner M, Goldacre MJ. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes 2012;5(4):532–40. doi: 10.1161/CIRCOUTCOMES.111.964700. [DOI] [PubMed]
  119. Brønnum-Hansen H, Davidsen M, Thorvaldsen P; Danish MONICA Study Group. Long-term survival and causes of death after stroke. Stroke 2001;32(9):2131–6. doi: 10.1161/hs0901.094253. [DOI] [PubMed]
  120. Health Economics Research Centre. HERC Database of Mapping Studies; 2020. www.herc.ox.ac.uk/downloads/herc-database-of-mapping-studies (accessed August 2021).
  121. University of Sheffield: School of Health and Related Research. Measuring and Valuing Health. www.sheffield.ac.uk/scharr/research/themes/valuing-health#SF-6D (accessed 2 September 2021).
  122. van den Berg B. SF-6D population norms. Health Econ 2012;21(12):1508–12. doi: 10.1002/hec.1823. [DOI] [PubMed]
  123. Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health 2010;13(5):509–18. doi: 10.1111/j.1524-4733.2010.00700.x. [DOI] [PubMed]
  124. Agledahl I, Hansen JB, Svartberg J. Impact of testosterone treatment on postprandial triglyceride metabolism in elderly men with subnormal testosterone levels. Scand J Clin Lab Invest 2008;68(7):641–8. doi: 10.1080/00365510801999068. [DOI] [PubMed]
  125. Sajatovic M, Chen P, Young R. Rating Scales in bipolar disorder. In Tohen M, Bowden CL, Nierenberg AA, Geddes JR, editors. Clinical Trial Design Challenges in Mood Disorders. Amsterdam: Academic Press; 2015.
  126. Grochtdreis T, Brettschneider C, Hajek A, Schierz K, Hoyer J, Koenig HH. Mapping the Beck depression inventory to the EQ-5D-3L in patients with depressive disorders. J Ment Health Policy Econ 2016;19(2):79–89. [PubMed]
  127. Stolk EA, Busschbach JJ, Caffa M, Meuleman EJ, Rutten FF. Cost utility analysis of sildenafil compared with papaverine–phentolamine injections. BMJ 2000;320(7243):1165–8. doi: 10.1136/bmj.320.7243.1165. [DOI] [PMC free article] [PubMed]
  128. Heald AH, Stedman M, Whyte M, Livingston M, Albanese M, Ramachandran S, Hackett G. Lessons learnt from the variation across 6741 family/general practices in England in the use of treatments for hypogonadism. Clin Endocrinol (Oxf) 2021;94(5):827–36. doi: 10.1111/cen.14412. [DOI] [PubMed]
  129. Electronic Medicines Compendium. Testogel 16.2 mg/g gel; 2015. URL: www.medicines.org.uk/emc/product/8919#gref (accessed August 2021).
  130. Nottinghamshire Area Prescribing Committee. Testosterone Replacement Therapy for Adult Male Hypogonadism; 2020. URL: www.nottsapc.nhs.uk/media/1261/testosterone-info-sheet.pdf?UNLID= (accessed August 2021).
  131. Bell C, Hadi MA, Khanal S, Paudyal V. Prescribing patterns and costs associated with erectile dysfunction drugs in England: a time trend analysis. BJGP Open 2021;5(2):bjgpopen20X101145. doi: 10.3399/bjgpopen20X101145. [DOI] [PMC free article] [PubMed]
  132. Medicines Complete. British National Formulary. London: Royal Pharmaceutical Society; 2018. URL: www.medicinescomplete.com/mc/bnf/current/index.htm (accessed 4 March 2020).
  133. Larsen K. Graphreader. URL: www.graphreader.com/ (accessed August 2021).
  134. Morales A, Johnston B, Heaton JP, Lundie M. Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J Urol 1997;157(3):849–54. doi: 10.1016/s0022-5347(01)65062-6. [DOI] [PubMed]
  135. National Clinical Guideline Centre. Appendix L: Cost-effectiveness Analysis: Low-intensity, Medium-intensity and High-intensity Statin Treatment for the Primary and Secondary Prevention of CVD (CG181). London: National Clinical Guideline Centre; 2014. URL: www.nice.org.uk/guidance/cg181/evidence/lipid-modification-update-appendices-pdf-243786638 (accessed 9 September 2020).
  136. National Institute for Health and Care Excellence. Peripheral arterial disease: diagnosis and management [CG147]; 2012. URL: www.nice.org.uk/guidance/cg147 (accessed August 2021).
  137. National Institute for Health and Care Excellence. Abdominal Aortic Aneurysm: Diagnosis and Management. NICE Guideline: Health Economics (NG156). London/Manchester: National Institute for Health and Care Excellence; 2020. URL: www.nice.org.uk/guidance/ng156/evidence/y-health-economics-appendix-pdf-255167681407 (accessed 9 September 2020).
  138. National Institute for Health and Care Excellence. Atrial Fibrillation and Heart Valve Disease: Self-monitoring Coagulation Status Using Point-of-care Coagulometers (the CoaguChek XS system) [DG14] 2014 Updated; 2017. URL: www.nice.org.uk/guidance/dg14 (accessed August 2021).
  139. Perkins GD, Ji C, Achana F, Black JJ, Charlton K, Crawford J, et al. Adrenaline to improve survival in out-of-hospital cardiac arrest: the PARAMEDIC2 RCT. Health Technol Assess 2021;25(25):1–166. doi: 10.3310/hta25250. [DOI] [PMC free article] [PubMed]
  140. NHS England. National Schedule of NHS Costs; 2020. URL: www.england.nhs.uk/wp-content/uploads/2021/06/National_Schedule_of_NHS_Costs_FY1920.xlsx (accessed August 2021).
  141. Curtis L, Burns A. Unit Costs of Health and Social Care 2020; 2020. URL: www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2020/ (accessed July 2021).
  142. NHS England. Arrhythmia 2018. URL: www.nhs.uk/conditions/arrhythmia/ (accessed August 2021).
  143. Burdett P, Lip GYH. Atrial fibrillation in the United Kingdom: predicting costs of an emerging epidemic recognising and forecasting the cost drivers of atrial fibrillation-related costs. Eur Heart J Qual Care Clin Outcomes 2020;8(2):187–94. https://doi.org/10.1093/ehjqcco/qcaa093. doi: 10.1093/ehjqcco/qcaa093. [DOI] [PubMed]
  144. Walker S, Asaria M, Manca A, Palmer S, Gale CP, Shah AD, et al. Long-term healthcare use and costs in patients with stable coronary artery disease: a population-based cohort using linked health records (CALIBER). Eur Heart J Qual Care Clin Outcomes 2016;2(2):125–40. doi: 10.1093/ehjqcco/qcw003. [DOI] [PMC free article] [PubMed]
  145. Danese MD, Gleeson M, Kutikova L, Griffiths RI, Azough A, Khunti K, et al. Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK. BMJ Open 2016;6(8):e011805. doi: 10.1136/bmjopen-2016-011805. [DOI] [PMC free article] [PubMed]
  146. NHS England. Why It’s Done - Aortic Valve Replacement; 2018. URL: www.nhs.uk/conditions/aortic-valve-replacement/whyitsdone/ (accessed August 2021).
  147. National Institute for Health and Care Excellence. Acute Heart Failure: Diagnosis and Management [CG187]; 2014. URL: www.nice.org.uk/guidance/cg187 (accessed August 2021). [PubMed]
  148. NHS England. 2019/20 National Cost Collection Data; 2020. URL: www.england.nhs.uk/national-cost-collection/#ncc1819 (accessed 26 November 2020).
  149. National Institute for Health and Care Excellence. Appendix K: Cost-Effectiveness Analysis: Supervised Exercise Compared to Unsupervised Exercise for the Treatment of People with Intermittent Claudication [NG147]. London/Manchester: National Institute for Health and Care Excellence; 2012. URL: www.nice.org.uk/guidance/cg147/evidence/appendices-an-pdf-186865022 (accessed 25 August 2021).
  150. Tappenden P, Chilcott JB. Avoiding and identifying errors and other threats to the credibility of health economic models. PharmacoEcon 2014;32(10):967–79. doi: 10.1007/s40273-014-0186-2. [DOI] [PubMed]
  151. ClinRisk Ltd. QRISK®3-2018 Risk Calculator; 2018. URL: https://qrisk.org/three/index.php (accessed August 2021).
  152. Briggs A, Claxton M, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
  153. Longworth L, Rowen D. NICE DSU Technical Support Document 10: The Use of Mapping Methods to Estimate Health State Utility Values. Sheffield: NICE Decision Support Unit, University of Sheffield; 2011. URL: http://nicedsu.org.uk/wp-content/uploads/2016/03/TSD-10-mapping-FINAL.pdf (accessed 24 March 2020). [PubMed]
  154. Park H, Park J, Kim K, Kang B, Baek S, Park N. Discontinuation of testosterone replacement therapy in patients with late-onset hypogonadism: a 10-year observational study. Eur Urol Open Sci 2020;19:e131.
  155. Budoff MJ, Ellenberg SS, Lewis CE, Mohler ER 3rd, Wenger NK, Bhasin S, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA 2017;317(7):708–16. doi: 10.1001/jama.2016.21043. [DOI] [PMC free article] [PubMed]
  156. Yeap BB, Grossmann M, McLachlan RI, Handelsman DJ, Wittert GA, Conway AJ, et al. Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations. Med J Aust 2016;205(5):228–31. doi: 10.5694/mja16.00448. [DOI] [PubMed]
  157. Wittert G, Bracken K, Robledo KP, Grossmann M, Yeap BB, Handelsman DJ, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol 2021;9(1):32–45. doi: 10.1016/S2213-8587(20)30367-3. [DOI] [PubMed]

RESOURCES